Roche Halts Development of SMA Candidate Olesoxime

Roche has halted development of olesoxime, the Phase III–bound spinal muscular atrophy (SMA) candidate it acquired three years ago when it bought Trophos.The company disclosed its decision in a letter Wednesday to SMA patient groups.“Since we bought olesoxime from Trophos in 2015, we have had many difficulties in developing this molecule for people with SMA,” Sangeeta Jethwa, M.D., Roche’s Head, Patient Partnership, Rare Diseases, said in the letter , dated May 30 and pos